Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07892300) titled 'Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer' on Oct. 17.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Diagnostic. Masking: None (Open Label).

Primary Sponsor: Oliver Jonas

Condition: Lung Cancer Mesothelioma Suspected Lung Cancer Suspected Mesothelioma

Intervention: Drug: Implantable Micro- drug delivery Microdevice (IMD)

Recruitment Status: Not recruiting

Phase: Early Phase 1

Date of First Enrollment: October 30, 2026

Target Sample Size: 20

To know more, visit https://clinicaltrials.gov/study...